Application of epigallocatechin gallate in preparing product for preventing and treating human mammary cancer disease

A technology of epigallocatechin and gallocatechin, which is applied in the field of preparation of drugs for the treatment of human breast cancer, and can solve the problems of no reports

Inactive Publication Date: 2008-09-24
YANTAI UNIV
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A large number of in vitro and animal experiments have proved that catechin and gallocatechin gallate can effectively inhibit the proliferation and metastasis of various tumor cells. The effect and mechanism of cancer prevention and treatment have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of epigallocatechin gallate in preparing product for preventing and treating human mammary cancer disease
  • Application of epigallocatechin gallate in preparing product for preventing and treating human mammary cancer disease
  • Application of epigallocatechin gallate in preparing product for preventing and treating human mammary cancer disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Formula: 810 grams of EGCG, 990 grams of medicinal starch.

[0031] Put the above-mentioned components into a blender, fully stir and mix, and pack capsules with a capsule machine, each filling 0.3 g, to obtain 6000 EGCG capsules, each containing 135 mg of EGCG.

[0032] 1. To establish the parameters of the effect of EGCG on blood VEGF, HGF and OPN, levels of MMP9 and MMP2 enzyme activities in human breast cancer patients.

[0033] The patient took 3 EGCG capsules (100 mg / grain) orally each time, three times a day, and took EGCG continuously for 8 weeks. Fasting for 15 hours before oral administration for the first time, after taking a blood sample (control) on an empty stomach, orally take three (100 mg / grain) EGCG capsules, take blood samples after 2 hours, separate serum and plasma, and set aside. After one week, two weeks, four weeks, six weeks and eight weeks, samples were analyzed in the same way. The levels of related proteins in serum and plasma were detected...

Embodiment 2

[0044] Decreased serum vascular endothelial growth factor (VEGF) levels in human breast cancer patients after taking EGCG, an active ingredient of tea.

[0045] Materials and methods

[0046] Twenty human breast cancer patients were randomly divided into two groups. There were 10 cases in the experimental group and 10 cases in the control group. Aged 37-73 years old (average 52 years old). All human breast cancer patients received radiotherapy instead of chemotherapeutic drugs. The experimental group took EGCG capsules (containing EGCG135mg / capsule), 3 times a day, 3 capsules each time, for 6 weeks, and the control group took no medicine. Blood samples were collected from patients at 0, 1, 4, and 6 weeks. Every time a blood sample is collected from the patient, after fasting for 14 hours, immediately take EGCG3 capsules, and take a blood sample 2 hours later, separate the serum and plasma from the blood samples taken with the drug and those without the drug, for the detect...

Embodiment 3

[0052] Decreased plasma hepatocyte growth factor (HGF) levels in human breast cancer patients following administration of tea active ingredient EGCG.

[0053] Materials and methods

[0054] Twenty human breast cancer patients were randomly divided into two groups. There were 10 cases in the experimental group and 10 cases in the control group. Aged 37-73 years old (average 52 years old). All human breast cancer patients received radiotherapy instead of chemotherapeutic drugs. The experimental group took EGCG capsules (containing EGCG135mg / capsule), 3 times a day, 3 capsules each time, for 6 weeks, and the control group took no medicine. Blood samples were collected from patients at 0, 1, 4, and 6 weeks. Every time a blood sample was collected from the patient, after 14 hours of fasting, 3 capsules of EGCG were taken immediately, and blood samples were collected 2 hours later. Serum and plasma were separated from the blood samples taken and not taken for the detection and a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the new drug use of EGCG ((Epigallocatechin-3-gallate) and the isomeride GCG (Gallocatechin-3-gallate) and particularly relates to the application of EGCG and GCG in the products of preventing and treating human breast cancers. EGCG and GCG play a better role in reducing the level of VEGF, HGF or OPN in the blood of a human breast cancer patient, lowering enzyme activity of MMP-9 and MMP-2 and preventing and treating human breast cancer.

Description

Technical field [0001] The present invention mainly relates to epigallocatechin gallate (epigallocatechin-3-gallate, EGCG) and its isomer gallocatechin gallate extracted from natural plants and / or obtained in chemical synthesis (Gallocatechin-3-gallate, GCG) new drug use, specifically relates to their application in the preparation of drugs for the treatment of human breast cancer, belongs to the technical field of traditional Chinese medicine. technical background [0002] The research on epigallocatechin gallate (EGCG) has been reported in the literature, and the reports on the therapeutic effects of EGCG can be summarized as anti-cancer, anti-oxidation, scavenging oxygen free radicals, anti-platelet aggregation, regulating body immunity, etc. [1] -10]. But so far, there is no application of EGCG and GCG for the treatment of human breast cancer. [0003] About 7 million people die of cancer every year in the world. Breast cancer is one of the tumors with the highest inci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61P35/00A61P15/14
Inventor 张国营刘珂刘昆王义善刘潜王珊于鹏飞黄艳卢兆桥
Owner YANTAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap